Treatment of Dyslipidemia in Statin-Intolerant Patients

Introduction to Statin-Intolerant Therapy

• The American Diabetes Association recommends initiating ezetimibe 10 mg daily as first-line therapy for patients unable to tolerate statins, then adding bempedoic acid 180 mg daily if LDL-C targets are not met, and reserving PCSK9 inhibitors for very high-risk patients with persistent LDL-C elevation 1, 2, 3

Confirming True Statin Intolerance

• Before pursuing alternative therapies, ensure the patient has attempted at least 2 different statins and has tried alternative dosing regimens, with adverse effects resolving or improving with dose reduction or discontinuation 1, 3, 4

Stepwise Treatment Algorithm

• Start ezetimibe 10 mg daily with meals for all statin-intolerant patients, reducing LDL-C by 15-20% as monotherapy 1, 3, 4
• If LDL-C targets are not achieved with ezetimibe alone, add bempedoic acid 180 mg daily, reducing LDL-C by 15-25% 1, 5, 4
• Reserve PCSK9 inhibitors for very high-risk patients with persistent LDL-C elevation, reducing LDL-C by approximately 50-60% 1, 2, 5, 4, 3

Risk-Based LDL-C Targets

• For very high-risk patients, target LDL-C <55 mg/dL with ≥50% reduction from baseline, and non-HDL-C <85 mg/dL 1, 2, 6, 4, 3
• For high-risk patients, target LDL-C <70 mg/dL, and non-HDL-C <100 mg/dL 6, 4, 3

Alternative Options for Specific Scenarios

• Consider bile acid sequestrants if triglycerides <300 mg/dL and patient cannot tolerate bempedoic acid, reducing LDL-C by 15-30% 4, 3
• For severe hypertriglyceridemia (>500 mg/dL), consider fenofibrate 160 mg daily to prevent acute pancreatitis 4

Essential Lifestyle Modifications

• Implement intensive dietary therapy alongside pharmacologic treatment, with saturated fats <7% of total calories, trans fatty acids <1% of total calories, and cholesterol <200 mg/day 4, 6, 3

Monitoring Strategy

• Obtain lipid profile at baseline, 4-12 weeks after initiating or changing therapy, then annually once at goal, and monitor liver enzymes (ALT/AST) at baseline when using bempedoic acid 6, 4

Critical Pitfalls to Avoid

• Don't assume statin intolerance without adequate trials, and don't jump directly to PCSK9 inhibitors without following the stepwise approach 3, 4
• Avoid using fenofibrate if triglycerides <500 mg/dL, and avoid all lipid-lowering drugs except bile acid sequestrants in women planning pregnancy, during pregnancy, or breastfeeding 4